Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 11/20 | 0.38 |
| ▸ | DRD2 | P14416 | 9/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26780351 | 0.83 | CNR1 (0.47) | POLBDRD4DRD2EPHX1CNR1 | |
| SCHEMBL19405480 | 0.80 | POLB (0.41) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL13617071 | 0.79 | POLB (0.50) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL22509442 | 0.79 | POLB (0.41) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL9355210 | 0.79 | POLB (0.57) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL18622113 | 0.79 | POLB (0.57) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL25590070 | 0.78 | CNR1 (0.49) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL25752842 | 0.78 | POLB (0.49) | POLBDRD4DRD2KDM4EMAPT | |
| SCHEMBL20442986 | 0.78 | POLB (0.40) | POLBDRD4DRD2ALDH1A1EPHX1 | |
| SCHEMBL10633351 | 0.77 | MEN1 (0.58) | POLBDRD4DRD2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | POLB 2345/4885DRD4 4549/4885DRD2 3766/4885 |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | ATF4, MAP3K10, EEF2K | POLB 1728/4885DRD4 4595/4885DRD2 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.